|
HU225496B1
(en)
|
1993-04-07 |
2007-01-29 |
Scios Inc |
Pharmaceutical compositions of prolonged delivery, containing peptides
|
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
|
US5641757A
(en)
|
1994-12-21 |
1997-06-24 |
Ortho Pharmaceutical Corporation |
Stable 2-chloro-2'-deoxyadenosine formulations
|
|
WO1998005351A1
(en)
|
1996-08-08 |
1998-02-12 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
DE69737479T4
(de)
|
1996-08-30 |
2010-05-06 |
Novo Nordisk A/S |
Glp-1 derivate
|
|
CA2277112C
(en)
|
1997-01-07 |
2008-08-26 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the reduction of food intake
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6723530B1
(en)
|
1997-02-05 |
2004-04-20 |
Amylin Pharmaceuticals, Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
|
DK1019077T4
(da)
|
1997-08-08 |
2011-03-07 |
Amylin Pharmaceuticals Inc |
Hidtil ukendte exendinagonistforbindelser
|
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
WO1999025727A2
(en)
|
1997-11-14 |
1999-05-27 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
|
JP2001523688A
(ja)
|
1997-11-14 |
2001-11-27 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
新規エキセンジン・アゴニスト化合物
|
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
AU760609B2
(en)
|
1998-01-09 |
2003-05-15 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
|
EP1056775B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
CA2321026A1
(en)
|
1998-03-09 |
1999-09-16 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
WO1999047160A1
(en)
|
1998-03-13 |
1999-09-23 |
Novo Nordisk A/S |
Stabilized aqueous peptide solutions
|
|
US6998387B1
(en)
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
|
NZ527473A
(en)
|
1998-06-12 |
2005-02-25 |
Amylin Pharmaceuticals Inc |
Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance
|
|
ES2553108T3
(es)
|
1998-08-10 |
2015-12-04 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diferenciación de células no productoras de insulina en células productoras de insulina mediante GLP-1 o exendina-4 y utilizaciones de las mismas
|
|
CA2343268A1
(en)
|
1998-09-17 |
2000-03-23 |
Eli Lilly And Company |
Protein formulations
|
|
US7259136B2
(en)
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
|
DE69928006T2
(de)
|
1998-12-22 |
2006-07-13 |
Eli Lilly And Co., Indianapolis |
Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
|
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
|
US20030087820A1
(en)
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
|
EP1143989B1
(en)
|
1999-01-14 |
2006-12-13 |
Amylin Pharmaceuticals, Inc. |
Exendins for glucagon suppression
|
|
EP1609478A1
(en)
|
1999-01-14 |
2005-12-28 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptide formulations
|
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
|
EP1956000B1
(en)
|
1999-03-17 |
2016-10-05 |
Novo Nordisk A/S |
Acylating agents useful for acylating peptides
|
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
CN1372570A
(zh)
|
1999-04-30 |
2002-10-02 |
安米林药品公司 |
修饰的exendin和exendin激动剂
|
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
CA2363712C
(en)
|
1999-05-17 |
2011-05-10 |
Conjuchem Inc. |
Long lasting insulinotropic peptides
|
|
US6482799B1
(en)
|
1999-05-25 |
2002-11-19 |
The Regents Of The University Of California |
Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
|
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US6972319B1
(en)
|
1999-09-28 |
2005-12-06 |
Bayer Pharmaceuticals Corporation |
Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
|
|
GB9930882D0
(en)
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
|
CA2396157A1
(en)
|
2000-01-10 |
2001-07-19 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
|
|
MXPA02009031A
(es)
|
2000-03-14 |
2004-08-19 |
Amylin Pharmaceuticals Inc |
Efectos del peptido-1(7-36) tipo glucagon en la motilidad antro-piloro.duodenal.
|
|
CA2380423A1
(en)
|
2000-05-17 |
2001-11-22 |
Bionebraska, Inc. |
Peptide pharmaceutical formulations
|
|
EP1282436B1
(en)
|
2000-05-19 |
2008-06-11 |
Amylin Pharmaceuticals, Inc. |
Treatment of acute coronary syndrome with glp-1
|
|
EP1317412A1
(en)
|
2000-08-18 |
2003-06-11 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US7507714B2
(en)
|
2000-09-27 |
2009-03-24 |
Bayer Corporation |
Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
|
|
ES2347137T3
(es)
|
2000-10-20 |
2010-10-26 |
Amylin Pharmaceuticals, Inc. |
Tratamiento de miocardio hibernante y cardiomiopatia diabetica con un peptido gpl-1.
|
|
DK1355942T3
(da)
|
2000-12-07 |
2008-11-17 |
Lilly Co Eli |
GLP-1-fusionsproteiner
|
|
MXPA03005135A
(es)
|
2000-12-13 |
2003-12-04 |
Lilly Co Eli |
Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon.
|
|
GB2371227A
(en)
|
2001-01-10 |
2002-07-24 |
Grandis Biotech Gmbh |
Crystallisation - resistant aqueous growth hormone formulations
|
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
|
AU2002308706A1
(en)
|
2001-06-01 |
2002-12-16 |
Eli Lilly And Company |
Glp-1 formulations with protracted time action
|
|
DE60224284T2
(de)
|
2001-06-28 |
2008-12-18 |
Novo Nordisk A/S |
Stabile formulierung von modifiziertem glp-1
|
|
EP1485707B1
(en)
|
2001-07-16 |
2009-01-14 |
caprotec bioanalytics GmbH |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
|
EP2022505B1
(en)
|
2001-07-31 |
2011-12-14 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
GLP-1, exendin-4, peptide analogs and uses thereof
|
|
US7238663B2
(en)
|
2001-08-28 |
2007-07-03 |
Eli Lilly And Company |
Pre-mixes of GLP-1 and basal insulin
|
|
EP1448222A4
(en)
|
2001-10-19 |
2006-05-17 |
Lilly Co Eli |
BIPHASIC MIXTURES OF GLP-1 AND INSULIN
|
|
AU2002364587A1
(en)
|
2001-12-21 |
2003-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
EP2261250B1
(en)
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
GCSF-Albumin fusion proteins
|
|
US7105489B2
(en)
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
|
JP4417113B2
(ja)
|
2002-02-20 |
2010-02-17 |
エミスフェアー・テクノロジーズ・インク |
Ｇｌｐ−１分子の投与方法
|
|
ES2311094T3
(es)
|
2002-02-27 |
2009-02-01 |
Immunex Corporation |
Composicion estabilizada de tnfr-fc que comprende arginina.
|
|
DK1502102T3
(da)
|
2002-03-11 |
2009-05-04 |
Caprotec Bioanalytics Gmbh |
Forbindelser og fremgangsmåder til analysering af proteomet
|
|
US7141240B2
(en)
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
|
WO2003084563A1
(en)
|
2002-04-04 |
2003-10-16 |
Novo Nordisk A/S |
Glp-1 agonist and cardiovascular complications
|
|
JP2005530732A
(ja)
|
2002-04-10 |
2005-10-13 |
イーライ・リリー・アンド・カンパニー |
胃不全麻痺の治療
|
|
US6861236B2
(en)
|
2002-05-24 |
2005-03-01 |
Applied Nanosystems B.V. |
Export and modification of (poly)peptides in the lantibiotic way
|
|
AU2003232172A1
(en)
|
2002-06-14 |
2003-12-31 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a glp-1 compound
|
|
US20040037826A1
(en)
|
2002-06-14 |
2004-02-26 |
Michelsen Birgitte Koch |
Combined use of a modulator of CD3 and a GLP-1 compound
|
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
|
ES2327328T3
(es)
|
2002-07-04 |
2009-10-28 |
Zealand Pharma A/S |
Glp-1 y procedimientos para el tratamiento de la diabetes.
|
|
US20070065469A1
(en)
|
2002-07-09 |
2007-03-22 |
Michael Betz |
Liquid formulations with high concentration of human growth hormone (high) comprising glycine
|
|
US20060165733A1
(en)
|
2002-07-09 |
2006-07-27 |
Michael Betz |
Liquid formulations with high concentration of hunan growth hormone (hgh) comprising phenol
|
|
WO2004012672A2
(en)
|
2002-08-01 |
2004-02-12 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
US20080260838A1
(en)
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
|
US20040038865A1
(en)
|
2002-08-01 |
2004-02-26 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
HRP20050157B1
(en)
|
2002-08-21 |
2013-01-31 |
Boehringer Ingelheim Pharma |
8-[3-amino-piperidin-1-yl]-xanthines,the production thereof and the use of the same as medicaments
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
US7544657B2
(en)
|
2002-10-02 |
2009-06-09 |
Zealand Pharma A/S |
Stabilized Exendin-4 compounds
|
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
SI1583541T1
(sl)
|
2002-11-20 |
2011-08-31 |
Neuronova Ab |
Spojine in postopki za povečanje nevrogeneze
|
|
AU2003297356A1
(en)
|
2002-12-17 |
2004-07-14 |
Amylin Pharmaceuticals, Inc. |
Prevention and treatment of cardiac arrhythmias
|
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
|
US20040209803A1
(en)
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
|
ES2512499T3
(es)
|
2003-04-08 |
2014-10-24 |
Yeda Research And Development Co., Ltd. |
Fármacos pegilados reversibles
|
|
WO2004089985A1
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
|
AU2004240630B2
(en)
|
2003-05-15 |
2010-10-07 |
Trustees Of Tufts College |
Stable analogs of peptide and polypeptide therapeutics
|
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
|
KR101128320B1
(ko)
|
2003-05-23 |
2012-04-12 |
넥타르 테라퓨틱스 |
아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
|
|
US8008255B2
(en)
|
2003-05-30 |
2011-08-30 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
|
JP2007524592A
(ja)
|
2003-06-03 |
2007-08-30 |
ノボ・ノルデイスク・エー／エス |
安定化された薬学的ペプチド組成物
|
|
JP4936884B2
(ja)
|
2003-06-03 |
2012-05-23 |
ノボ・ノルデイスク・エー／エス |
安定化された薬学的ペプチド組成物
|
|
CA2527743A1
(en)
|
2003-06-03 |
2004-12-09 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
|
ATE529126T1
(de)
|
2003-06-03 |
2011-11-15 |
Novo Nordisk As |
Stabilisierte pharmazeutische peptid zusammensetzungen
|
|
US8921311B2
(en)
|
2003-08-01 |
2014-12-30 |
Mannkind Corporation |
Method for treating hyperglycemia
|
|
EP2264065B1
(en)
|
2003-08-05 |
2017-03-08 |
Novo Nordisk A/S |
Novel insulin derivatives
|
|
WO2005019261A1
(en)
|
2003-08-21 |
2005-03-03 |
Novo Nordisk A/S |
Separation of polypeptides comprising a racemized amino acid
|
|
EP1663295A2
(en)
|
2003-09-01 |
2006-06-07 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
US20060247167A1
(en)
|
2003-09-01 |
2006-11-02 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
JP2007537981A
(ja)
|
2003-09-19 |
2007-12-27 |
ノボ ノルディスク アクティーゼルスカブ |
新規の血漿タンパク質親和性タグ
|
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
|
ES2373660T3
(es)
|
2003-11-13 |
2012-02-07 |
Novo Nordisk A/S |
Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
|
|
US20050281879A1
(en)
|
2003-11-14 |
2005-12-22 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
US20050106214A1
(en)
|
2003-11-14 |
2005-05-19 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
CN1882356B
(zh)
|
2003-11-20 |
2015-02-25 |
诺沃挪第克公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
|
WO2005081619A2
(en)
|
2003-11-20 |
2005-09-09 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
EP1692168B1
(en)
|
2003-12-03 |
2011-07-20 |
Novo Nordisk A/S |
Single-chain insulin
|
|
JP2007513965A
(ja)
|
2003-12-10 |
2007-05-31 |
ネクター セラピューティクス アラバマ，コーポレイション |
ポリマー・活性剤複合体の二つの集団を含む組成物
|
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
US20050143303A1
(en)
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
|
CN1938334A
(zh)
|
2004-01-30 |
2007-03-28 |
瓦拉塔药品公司 |
Glp－1激动剂和胃泌素化合物的联合使用
|
|
EP2335715A3
(en)
|
2004-02-11 |
2013-12-18 |
Amylin Pharmaceuticals, LLC |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
EP1718665B1
(en)
|
2004-02-11 |
2013-04-10 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
|
JP2008500281A
(ja)
|
2004-02-11 |
2008-01-10 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
アミリンファミリーペプチドおよびそれらを作成し使用するための方法
|
|
US7399744B2
(en)
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
|
CN1968700A
(zh)
|
2004-04-15 |
2007-05-23 |
阿尔克姆斯有限公司 |
聚合物基的持续释放装置
|
|
US20060110423A1
(en)
|
2004-04-15 |
2006-05-25 |
Wright Steven G |
Polymer-based sustained release device
|
|
US7456254B2
(en)
|
2004-04-15 |
2008-11-25 |
Alkermes, Inc. |
Polymer-based sustained release device
|
|
WO2005117584A2
(en)
|
2004-05-28 |
2005-12-15 |
Amylin Pharmaceuticals, Inc |
Improved transmucosal delivery of peptides and proteins
|
|
US20090069226A1
(en)
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
|
EP1758575A1
(en)
|
2004-06-11 |
2007-03-07 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using glp-1 agonists
|
|
US20070021346A1
(en)
|
2005-05-26 |
2007-01-25 |
Ewing William R |
N-terminally modified GLP-1 receptor modulators
|
|
US7875700B2
(en)
|
2004-07-19 |
2011-01-25 |
Biocon Limited |
Cation complexes of insulin compound conjugates, formulation and uses thereof
|
|
US7638299B2
(en)
|
2004-07-21 |
2009-12-29 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
|
BRPI0514115A
(pt)
|
2004-08-03 |
2008-05-27 |
Biorexis Technology Inc |
terapia de combinação empregando-se proteìnas de fusão de transferrina compreendendo glp-1
|
|
JP4965446B2
(ja)
|
2004-08-31 |
2012-07-04 |
ノヴォ ノルディスク アー／エス |
ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス（ヒドロキシメチル）アミノメタンの使用
|
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
EP1791554A2
(en)
|
2004-09-17 |
2007-06-06 |
Novo Nordisk A/S |
Pharmaceutical compositions containing insulin and insulinotropic peptide
|
|
KR101506925B1
(ko)
|
2004-10-01 |
2015-03-30 |
램스코르 인코포레이티드 |
편리하게 이식가능한 서방형 약물 조성물
|
|
WO2006037811A2
(en)
|
2004-10-07 |
2006-04-13 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
|
US7595294B2
(en)
|
2004-10-08 |
2009-09-29 |
Transition Therapeutics, Inc. |
Vasoactive intestinal polypeptide pharmaceuticals
|
|
JP4944034B2
(ja)
|
2004-10-13 |
2012-05-30 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
Ｐｔｐ１ｂ発現のアンチセンス調節
|
|
US7442682B2
(en)
|
2004-10-19 |
2008-10-28 |
Nitto Denko Corporation |
Transepithelial delivery of peptides with incretin hormone activities
|
|
CN101056650A
(zh)
|
2004-11-12 |
2007-10-17 |
诺和诺德公司 |
促胰岛素肽的稳定制剂
|
|
WO2006051110A2
(en)
|
2004-11-12 |
2006-05-18 |
Novo Nordisk A/S |
Stable formulations of insulinoptropic peptides
|
|
ES2575984T3
(es)
|
2004-11-12 |
2016-07-04 |
Novo Nordisk A/S |
Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
|
|
SG157423A1
(en)
|
2004-12-02 |
2009-12-29 |
Domantis Ltd |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
|
AU2005316524B2
(en)
|
2004-12-13 |
2012-01-12 |
Amylin Pharmaceuticals, Llc |
Pancreatic Polypeptide Family motifs, polypeptides and methods comprising the same
|
|
EP1827501B2
(en)
|
2004-12-21 |
2013-11-20 |
Nektar Therapeutics |
Stabilized polymeric thiol reagents
|
|
CN101044162B
(zh)
|
2004-12-22 |
2010-10-27 |
伊莱利利公司 |
Glp-1类似物融合蛋白质制剂
|
|
US20070021336A1
(en)
|
2004-12-24 |
2007-01-25 |
Christen Anderson |
Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis
|
|
EP1845105A4
(en)
|
2005-01-14 |
2009-02-18 |
Wuxi Grandchamp Pharmaceutical |
MODIFIED EXENDINES AND CORRESPONDING USES
|
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
|
WO2006082588A2
(en)
|
2005-02-07 |
2006-08-10 |
Pharmalight Inc. |
Method and device for ophthalmic administration of active pharmaceutical ingredients
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
EP1853627A2
(en)
|
2005-02-11 |
2007-11-14 |
Amylin Pharmaceuticals, Inc. |
Gip analog and hybrid polypeptides with selectable properties
|
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
|
EP1888103B1
(en)
|
2005-04-11 |
2012-03-21 |
Amylin Pharmaceuticals, Inc. |
Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
|
|
WO2006114396A1
(en)
|
2005-04-24 |
2006-11-02 |
Novo Nordisk A/S |
Injection device
|
|
EP1888118B1
(en)
|
2005-05-25 |
2016-08-17 |
Novo Nordisk A/S |
Polypeptide formulations stabilized with ethylenediamine
|
|
ES2399645T3
(es)
|
2005-06-06 |
2013-04-02 |
Camurus Ab |
Formulaciones de análogos de GLP-1
|
|
GB0511986D0
(en)
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
WO2006134340A2
(en)
|
2005-06-13 |
2006-12-21 |
Imperial Innovations Limited |
Oxyntomodulin analogues and their effects on feeding behaviour
|
|
CN101242858B
(zh)
|
2005-06-16 |
2012-12-19 |
尼克塔治疗公司 |
具有可降解键的轭合物以及用于制备这种轭合物的聚合物试剂
|
|
EP2099495A2
(en)
|
2005-08-04 |
2009-09-16 |
Nektar Therapeutics AL, Corporation |
Conjugates of a g-csf moiety and a polymer
|
|
WO2007016764A1
(en)
|
2005-08-06 |
2007-02-15 |
Qinghua Wang |
Composition and method for prevention and treatment of type i diabetes
|
|
EP1922336B1
(en)
|
2005-08-11 |
2012-11-21 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
|
PT3524261T
(pt)
|
2005-08-19 |
2024-01-12 |
Amylin Pharmaceuticals Llc |
Exendina para o tratamento da diabetes e redução do peso corporal
|
|
IN2014DN09128A
(cg-RX-API-DMAC7.html)
|
2005-09-14 |
2015-07-10 |
Mannkind Corp |
|
|
BRPI0616195A2
(pt)
|
2005-09-20 |
2011-06-14 |
Novartis Ag |
uso de um inibidor de dpp-iv para reduzir eventos hipoglicÊmicos
|
|
WO2007047834A2
(en)
|
2005-10-18 |
2007-04-26 |
Biocon Limited |
Oral peptide conjugates for metabolic diseases
|
|
US7687608B2
(en)
|
2005-10-19 |
2010-03-30 |
Smartcells, Inc. |
Methods for reducing the mitogenicity of lectin compositions
|
|
US8338368B2
(en)
|
2005-11-07 |
2012-12-25 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
WO2007053946A1
(en)
|
2005-11-09 |
2007-05-18 |
Conjuchem Biotechnologies Inc. |
Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
|
|
EP1968607B1
(en)
|
2005-12-02 |
2014-01-15 |
Nabil Habib Lab |
Treatment of cancer and other diseases
|
|
EP1965828A2
(en)
|
2005-12-02 |
2008-09-10 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
|
|
BRPI0620571A2
(pt)
|
2005-12-08 |
2011-11-22 |
Nastech Pharm Co |
formulação farmacêutica aquosa, forma de dosagem de exendina, solução aquosa, uso de uma formulação farmacêutica, e uso de uma formulação farmacêutica aquosa
|
|
JP5096363B2
(ja)
|
2005-12-16 |
2012-12-12 |
ネクター セラピューティックス |
Ｇｌｐ−１のポリマ複合体
|
|
US8334257B2
(en)
|
2005-12-20 |
2012-12-18 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
|
US8178495B2
(en)
|
2008-06-27 |
2012-05-15 |
Duke University |
Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
|
|
JP5242415B2
(ja)
|
2006-01-18 |
2013-07-24 |
フォアシーエイサー ファーマシューティカルズ インコーポレイテッド |
高い安定性を持つ薬理組成物
|
|
WO2007092772A2
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Inc. |
Protein formulations
|
|
US7704953B2
(en)
|
2006-02-17 |
2010-04-27 |
Mdrna, Inc. |
Phage displayed cell binding peptides
|
|
JP5412273B2
(ja)
|
2006-03-21 |
2014-02-12 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
ペプチド−ぺプチダーゼ阻害剤及びその使用
|
|
RU2419452C2
(ru)
|
2006-04-13 |
2011-05-27 |
Ипсен Фарма С.А.С. |
ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ hGLP-1, ЭКСЕНДИНА-4 И ИХ АНАЛОГОВ
|
|
KR20150042304A
(ko)
|
2006-04-14 |
2015-04-20 |
맨카인드 코포레이션 |
글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
WO2007133778A2
(en)
|
2006-05-12 |
2007-11-22 |
Amylin Pharmaceuticals, Inc. |
Methods to restore glycemic control
|
|
EA200870575A1
(ru)
*
|
2006-05-26 |
2009-08-28 |
Амилин Фармасьютикалз, Инк. |
Композиции и способы лечения застойной сердечной недостаточности
|
|
WO2007139589A1
(en)
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
|
PT2038423E
(pt)
|
2006-06-21 |
2013-03-27 |
Biocon Ltd |
Método de produção de um polipéptido biologicamente activo possuindo actividade insulinotrópica
|
|
SI2494959T1
(sl)
|
2006-07-05 |
2015-04-30 |
Foamix Pharmaceuticals Ltd. |
Penilno sredstvo dikarboksilne kisline in njega farmacevtski sestavki
|
|
AU2007278994B2
(en)
|
2006-07-24 |
2013-08-15 |
Biorexis Pharmaceutical Corporation |
Exendin fusion proteins
|
|
US7928186B2
(en)
|
2006-08-02 |
2011-04-19 |
Phoenix Pharmaceuticals, Inc. |
Cell permeable bioactive peptide conjugates
|
|
US20090325860A1
(en)
|
2006-08-04 |
2009-12-31 |
Nastech Pharmaceutical Company Inc. |
Compositions for intranasal delivery of human insulin and uses thereof
|
|
KR101200728B1
(ko)
|
2006-08-09 |
2012-11-13 |
인타르시아 세라퓨틱스 인코포레이티드 |
삼투성 전달 시스템 및 피스톤 조립체
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
WO2008021560A2
(en)
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
Dpp-iv resistant gip hybrid polypeptides with selectable properties
|
|
EP2057189B1
(en)
*
|
2006-08-25 |
2013-03-06 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
|
CN102827284B
(zh)
|
2006-11-14 |
2015-07-29 |
上海仁会生物制药股份有限公司 |
带有聚乙二醇基团的Exendin或其类似物及其制剂和用途
|
|
EP2124883A2
(en)
|
2006-12-12 |
2009-12-02 |
Amylin Pharmaceuticals, Inc. |
Pharmaceutical formulations and methods for making the same
|
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
|
CN101663317A
(zh)
|
2007-01-05 |
2010-03-03 |
CovX科技爱尔兰有限公司 |
胰高血糖素样蛋白-1受体glp-1r激动剂化合物
|
|
EP2124974B1
(en)
|
2007-01-05 |
2017-03-15 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
|
|
RU2432361C2
(ru)
|
2007-01-05 |
2011-10-27 |
КовЭкс Текнолоджиз Айэлэнд Лимитед |
Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
|
|
WO2008098212A2
(en)
|
2007-02-08 |
2008-08-14 |
Diobex, Inc. |
Extended release formulations of glucagon and other peptides and proteins
|
|
US8454971B2
(en)
|
2007-02-15 |
2013-06-04 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
|
WO2008130066A1
(en)
|
2007-04-20 |
2008-10-30 |
Kang Choon Lee |
Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
|
|
RU2440097C2
(ru)
|
2007-04-23 |
2012-01-20 |
Интарсия Терапьютикс, Инк. |
Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
|
|
US8236760B2
(en)
|
2007-04-27 |
2012-08-07 |
Cedars-Sinsai Medical Center |
Use of GLP-1 receptor agonists for the treatment of short bowel syndrome
|
|
US7829664B2
(en)
|
2007-06-01 |
2010-11-09 |
Boehringer Ingelheim International Gmbh |
Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
|
|
EP2164519A2
(en)
|
2007-06-08 |
2010-03-24 |
Ascendis Pharma AS |
Long-acting polymeric prodrugs of exendin
|
|
US7994122B2
(en)
|
2007-06-15 |
2011-08-09 |
Zealand Pharma A/S |
Glucagon analogues
|
|
EP2175834B8
(en)
|
2007-07-10 |
2012-08-22 |
Eli Lilly And Company |
Glp-1-fc fusion protein formulation
|
|
CA2693504A1
(en)
|
2007-08-03 |
2009-02-12 |
Eli Lilly And Company |
Treatment for obesity
|
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
|
NZ599756A
(en)
|
2007-08-30 |
2013-09-27 |
Curedm Group Holdings Llc |
Compositions and methods of using proislet peptides and analogs thereof
|
|
WO2009030771A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
US20100256056A1
(en)
|
2007-09-07 |
2010-10-07 |
Zheng Xin Dong |
Analogues of exendin-4 and exendin-3
|
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
|
HUE025485T2
(en)
|
2007-10-24 |
2016-02-29 |
Mannkind Corp |
Respiratory dry powder formulation containing GLP-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
|
|
AU2008316636B2
(en)
|
2007-10-24 |
2014-02-06 |
Mannkind Corporation |
Delivery of active agents
|
|
MX2010004297A
(es)
|
2007-10-30 |
2010-05-03 |
Univ Indiana Res & Tech Corp |
Antagonistas de glucagon.
|
|
ES2558155T3
(es)
|
2007-10-30 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
|
|
CN107412742B
(zh)
|
2007-11-16 |
2022-03-15 |
诺沃—诺迪斯克有限公司 |
包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物
|
|
WO2009067268A1
(en)
|
2007-11-23 |
2009-05-28 |
Michael Rothkopf |
Methods of enhancing diabetes resolution
|
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
JP2011506442A
(ja)
|
2007-12-11 |
2011-03-03 |
コンジュケム バイオテクノロジーズ インコーポレイテッド |
インスリン分泌性ペプチド結合体の製剤
|
|
BRPI0907371A2
(pt)
|
2008-01-09 |
2015-11-24 |
Sanofi Aventis Deutschland |
derivados de insulina com um perfil de tempo-ação muito retardado
|
|
EP2249853A4
(en)
|
2008-01-30 |
2012-12-26 |
Univ Indiana Res & Tech Corp |
ESTER BASED PEPTIDE PRODRUGS
|
|
RS58948B1
(sr)
|
2008-02-01 |
2019-08-30 |
Ascendis Pharma As |
Prolek koji sadrži linker koji se može sam odcepiti
|
|
MY161108A
(en)
|
2008-02-06 |
2017-04-14 |
Biocon Ltd |
Fermentation medias and processes thereof
|
|
WO2009114959A1
(zh)
|
2008-03-20 |
2009-09-24 |
中国人民解放军军事医学科学院毒物药物研究所 |
可注射用缓释药物制剂及其制备方法
|
|
WO2009125423A2
(en)
|
2008-04-07 |
2009-10-15 |
National Institute Of Immunology |
Compositions useful for the treatment of diabetes and other chronic disorder
|
|
TW200950799A
(en)
|
2008-05-07 |
2009-12-16 |
Merrion Res Iii Ltd |
Compositions of GnRH related compounds and processes of preparation
|
|
ES2552646T3
(es)
|
2008-05-21 |
2015-12-01 |
Amylin Pharmaceuticals, Inc. |
Exendinas para disminuir el colesterol y los triglicéridos
|
|
WO2009143014A1
(en)
|
2008-05-23 |
2009-11-26 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist bioassays
|
|
CN109568740B
(zh)
|
2008-06-13 |
2022-05-27 |
曼金德公司 |
干粉吸入器和用于药物输送的系统
|
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
|
US9358352B2
(en)
|
2008-06-13 |
2016-06-07 |
Mannkind Corporation |
Dry powder drug delivery system and methods
|
|
KR20110039230A
(ko)
|
2008-06-17 |
2011-04-15 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
|
|
JP5775450B2
(ja)
|
2008-06-17 |
2015-09-09 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
グルカゴン／ｇｌｐ−１受容体コアゴニスト
|
|
TWI474835B
(zh)
|
2008-06-17 |
2015-03-01 |
Univ Indiana Res & Tech Corp |
用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
|
|
CN102083854A
(zh)
|
2008-06-17 |
2011-06-01 |
大塚化学株式会社 |
附加了糖链的glp-1肽
|
|
EP2303247A4
(en)
|
2008-07-21 |
2012-08-01 |
Syneron Medical Ltd |
TRANSDERMALES SYSTEM FOR THE EXTENDED RELEASE OF INCRETINS AND INCRETIN MIMETIC PEPTIDES
|
|
WO2010013012A2
(en)
|
2008-08-01 |
2010-02-04 |
Lund University Bioscience Ab |
Novel polypeptides and uses thereof
|
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
RS59913B1
(sr)
|
2008-10-17 |
2020-03-31 |
Sanofi Aventis Deutschland |
Kombinacija insulina i glp-1-agonista
|
|
ES2620610T3
(es)
|
2008-12-10 |
2017-06-29 |
Glaxosmithkline Llc |
Composiciones farmacéuticas de albiglutide
|
|
MX2011006314A
(es)
|
2008-12-15 |
2011-09-22 |
Zealand Pharma As |
Analogos de glucagon.
|
|
CN102282166B
(zh)
|
2008-12-15 |
2015-04-01 |
西兰制药公司 |
胰高血糖素类似物
|
|
MA32970B1
(fr)
|
2008-12-15 |
2012-01-02 |
Zealand Pharma As |
Analogues du glucagon
|
|
EP2370462B1
(en)
|
2008-12-15 |
2014-07-16 |
Zealand Pharma A/S |
Glucagon analogues
|
|
RU2550696C2
(ru)
|
2008-12-19 |
2015-05-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Основанные на амидах пролекарства пептидов глюкагонового надсемейства
|
|
CN101538323B
(zh)
|
2009-01-13 |
2012-05-09 |
深圳翰宇药业股份有限公司 |
一种纯化艾塞那肽的方法
|
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
|
KR101733816B1
(ko)
|
2009-03-04 |
2017-05-08 |
맨카인드 코포레이션 |
개선된 건조 분말 약물 전달 시스템
|
|
WO2010100241A1
(en)
|
2009-03-05 |
2010-09-10 |
Sanofi-Aventis Deutschland Gmbh |
Drug delivery device with retractable needle
|
|
US8642544B2
(en)
|
2009-04-01 |
2014-02-04 |
Amylin Pharmaceuticals, Llc |
N-terminus conformationally constrained GLP-1 receptor agonist compounds
|
|
WO2010118034A2
(en)
|
2009-04-06 |
2010-10-14 |
Board Of Regents, The University Of Texas System |
Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
|
|
RU2503688C2
(ru)
|
2009-04-22 |
2014-01-10 |
Алтеоген, Инк |
Слитый белок или пептид с увеличенным временем полужизни in vivo, поддерживаемый за счет замедленного высвобождения in vivo, и способ увеличения времени полужизни in vivo с его применением
|
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
|
CN101559041B
(zh)
|
2009-05-19 |
2014-01-15 |
中国科学院过程工程研究所 |
粒径均一的多肽药物缓释微球或微囊制剂及制备方法
|
|
WO2010133675A1
(en)
|
2009-05-20 |
2010-11-25 |
Sanofi-Aventis Deutschland Gmbh |
A bung for drug containing cartridges in drug delivery devices
|
|
DK3189868T3
(da)
|
2009-05-20 |
2025-01-13 |
Sanofi Aventis Deutschland |
Prop til lægemiddelholdige patroner i lægemiddelfremføringsanordninger omfattende et elektronisk kodningselement
|
|
US20120231022A1
(en)
|
2009-05-28 |
2012-09-13 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
|
EP2440235A1
(en)
|
2009-06-11 |
2012-04-18 |
Novo Nordisk A/S |
Glp-1 and fgf21 combinations for treatment of diabetes type 2
|
|
EP2443146B1
(en)
|
2009-06-16 |
2016-10-05 |
Indiana University Research And Technology Corporation |
Gip receptor-active glucagon compounds
|
|
RU2012103240A
(ru)
|
2009-07-02 |
2013-08-10 |
Ангиокем Инк. |
Мультимерные пептидные конъюгаты и их применение
|
|
AP3329A
(en)
|
2009-07-13 |
2015-06-30 |
Zealand Pharma As |
Acylated glucagon analogues
|
|
CN101601646B
(zh)
|
2009-07-22 |
2011-03-23 |
南京凯瑞尔纳米生物技术有限公司 |
治疗糖尿病的鼻腔滴剂及其制备方法
|
|
WO2011011675A1
(en)
|
2009-07-23 |
2011-01-27 |
Zelos Therapeutics, Inc. |
Pharmaceutically acceptable formulations/compositions for peptidyl drugs
|
|
KR20120089843A
(ko)
|
2009-07-31 |
2012-08-14 |
사노피-아벤티스 도이칠란트 게엠베하 |
인슐린 링커 접합체를 포함한 프로드럭
|
|
WO2011016030A1
(en)
*
|
2009-08-03 |
2011-02-10 |
Technion Research & Development Foundation Ltd. |
Hydrogen production by an autothermal heat exchanger packed-bed membrane gas reformer
|
|
WO2011017835A1
(en)
|
2009-08-11 |
2011-02-17 |
Nanjing University |
Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
|
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
|
US20120148586A1
(en)
*
|
2009-08-27 |
2012-06-14 |
Joyce Ching Tsu Chou |
Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
|
|
CN104147611A
(zh)
|
2009-09-30 |
2014-11-19 |
葛兰素集团有限公司 |
具有延长的半衰期的药物融合体和缀合物
|
|
US20110097386A1
(en)
|
2009-10-22 |
2011-04-28 |
Biodel, Inc. |
Stabilized glucagon solutions
|
|
WO2011049713A2
(en)
|
2009-10-22 |
2011-04-28 |
Biodel Inc. |
Stabilized glucagon solutions
|
|
US9610329B2
(en)
|
2009-10-22 |
2017-04-04 |
Albireo Pharma, Inc. |
Stabilized glucagon solutions
|
|
JPWO2011052523A1
(ja)
|
2009-10-30 |
2013-03-21 |
株式会社糖鎖工学研究所 |
抗原性ｇｌｐ−１アナログの糖鎖付加体
|
|
EP2496583B1
(en)
|
2009-11-02 |
2014-12-10 |
Pfizer Inc |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
|
|
US20120294855A1
(en)
|
2009-11-03 |
2012-11-22 |
Eli Lilly & Company |
Glp-1 receptor agonist compounds for obstructive sleep apnea
|
|
ES2534191T3
(es)
|
2009-11-13 |
2015-04-20 |
Sanofi-Aventis Deutschland Gmbh |
Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
|
|
CA2780043C
(en)
|
2009-11-13 |
2019-01-29 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
|
JP2013514371A
(ja)
|
2009-12-15 |
2013-04-25 |
メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー |
肥満および他の代謝性疾患の処置のためのＰＰＡＲγ温存チアゾリジンジオンならびに組み合わせ物
|
|
CN102753170A
(zh)
|
2009-12-15 |
2012-10-24 |
新陈代谢解决方案开发公司 |
治疗糖尿病及其它代谢性疾病的ppar节制的噻唑烷二酮和组合
|
|
DK2512470T3
(en)
|
2009-12-15 |
2017-02-27 |
Octeta Therapeutics Llc |
PPAR SAVING THIAZOLIDE INDIA AND COMBINATIONS TO TREAT NEURODEGENERATIVE DISEASES
|
|
JP5634526B2
(ja)
|
2009-12-15 |
2014-12-03 |
メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー |
代謝性疾患を処置するためのｐｐａｒ温存チアゾリジンジオン塩
|
|
CN102791731B
(zh)
|
2009-12-16 |
2016-04-20 |
诺沃—诺迪斯克有限公司 |
Glp-1类似物和衍生物
|
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
|
CN102933200B
(zh)
|
2009-12-18 |
2015-11-25 |
莱迪杜德制药公司 |
包含磷脂的单相凝胶组合物
|
|
CN101798588B
(zh)
|
2009-12-21 |
2015-09-09 |
上海仁会生物制药股份有限公司 |
Glp-1受体激动剂生物学活性测定方法
|
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
|
AR079345A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina
|
|
PH12012501494A1
(en)
|
2010-01-20 |
2012-10-22 |
Zealand Pharma As |
Treatment of cardiac conditions
|
|
IN2012DN06437A
(cg-RX-API-DMAC7.html)
|
2010-01-27 |
2015-10-09 |
Univ Indiana Res & Tech Corp |
|
|
KR101772855B1
(ko)
|
2010-02-01 |
2017-08-31 |
사노피-아벤티스 도이칠란트 게엠베하 |
카트리지 홀더, 약물 전달 장치 및 카트리지를 카트리지 홀더에 고정시키기 위한 방법
|
|
WO2011109784A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Formulation of insulinotropic peptide conjugates
|
|
AR080592A1
(es)
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
|
WO2011117415A1
(en)
|
2010-03-26 |
2011-09-29 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
CN103079587B
(zh)
|
2010-05-13 |
2016-05-11 |
印第安纳大学研究及科技有限公司 |
呈现核激素受体活性的胰高血糖素超家族肽
|
|
KR20130111923A
(ko)
|
2010-05-13 |
2013-10-11 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
WO2011144751A1
(en)
|
2010-05-20 |
2011-11-24 |
Glaxo Group Limited |
Improved anti-serum albumin binding variants
|
|
CN102918177B
(zh)
|
2010-05-31 |
2015-09-09 |
株式会社捷太格特 |
覆盖部件的制造方法
|
|
CN102906981B
(zh)
|
2010-06-01 |
2016-03-16 |
本田技研工业株式会社 |
Dc/dc转换器的控制装置
|
|
WO2011156407A2
(en)
|
2010-06-09 |
2011-12-15 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonists to treat pancre-atitis
|
|
CN101891823B
(zh)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
|
US8636711B2
(en)
|
2010-06-14 |
2014-01-28 |
Legacy Emanuel Hospital & Health Center |
Stabilized glucagon solutions and uses therefor
|
|
UY33462A
(es)
*
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
RU2580317C2
(ru)
|
2010-06-24 |
2016-04-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
|
|
US9234023B2
(en)
|
2010-06-24 |
2016-01-12 |
Biousian Biosystems, Inc. |
Glucagon-like peptide-1 glycopeptides
|
|
WO2011163473A1
(en)
|
2010-06-25 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
|
|
WO2012012460A1
(en)
|
2010-07-19 |
2012-01-26 |
Xeris Pharmaceuticals, Inc. |
Stable glucagon formulations for the treatment of hypoglycemia
|
|
US20130137645A1
(en)
|
2010-07-19 |
2013-05-30 |
Mary S. Rosendahl |
Modified peptides and proteins
|
|
JP2013535471A
(ja)
|
2010-07-28 |
2013-09-12 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
安定化した領域を有するｇｌｐ−１受容体アゴニスト化合物
|
|
CN102397558B
(zh)
|
2010-09-09 |
2013-08-14 |
中国人民解放军军事医学科学院毒物药物研究所 |
Exendin-4类似物的定位聚乙二醇化修饰物及其用途
|
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
|
CA2812951A1
(en)
|
2010-09-28 |
2012-04-19 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides having enhanced duration of action
|
|
JP5894174B2
(ja)
|
2010-11-03 |
2016-03-23 |
アレコー リミテッド |
グルカゴンを含む新規組成物
|
|
JP6092113B2
(ja)
|
2010-11-09 |
2017-03-08 |
マンカインド コーポレイション |
セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物
|
|
EP2460552A1
(en)
|
2010-12-06 |
2012-06-06 |
Sanofi-Aventis Deutschland GmbH |
Drug delivery device with locking arrangement for dose button
|
|
CN102552883B
(zh)
|
2010-12-09 |
2014-02-19 |
天津药物研究院 |
一种多肽复合物、药物组合物、其制备方法和应用
|
|
PT2651398T
(pt)
|
2010-12-16 |
2018-03-09 |
Novo Nordisk As |
Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
|
|
EA201390941A1
(ru)
|
2010-12-22 |
2013-12-30 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Аналоги глюкагона, проявляющие активность на рецепторе gip
|
|
US9161953B2
(en)
|
2010-12-22 |
2015-10-20 |
Amylin Pharmaceuticals, Llc |
GLP-1 receptor agonists for islet cell transplantation
|
|
CN102532301B
(zh)
|
2010-12-31 |
2014-09-03 |
上海医药工业研究院 |
一类新型的Exendin-4类似物及其制备方法
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
CN102100906A
(zh)
|
2011-02-18 |
2011-06-22 |
深圳翰宇药业股份有限公司 |
一种艾塞那肽的药用制剂及其制备方法
|
|
MX342675B
(es)
|
2011-03-10 |
2016-10-07 |
Xeris Pharmaceuticals Inc |
Formulaciones estables para inyeccion parenteral de farmacos de peptido.
|
|
CN102718858B
(zh)
|
2011-03-29 |
2014-07-02 |
天津药物研究院 |
胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
|
|
CN106928341B
(zh)
|
2011-03-30 |
2021-06-01 |
上海仁会生物制药股份有限公司 |
定点单取代聚乙二醇化Exendin类似物及其制备方法
|
|
DK2694095T3
(en)
|
2011-04-05 |
2018-05-28 |
Longevity Biotech Inc |
COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
|
|
EP2696897A2
(en)
|
2011-04-11 |
2014-02-19 |
Yeda Research and Development Co. Ltd. |
Albumin binding probes and drug conjugates thereof
|
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
|
CN102766204B
(zh)
|
2011-05-05 |
2014-10-15 |
天津药物研究院 |
胰高血糖素样肽-1突变体多肽及其制备方法和其应用
|
|
CA3134906A1
(en)
|
2011-05-18 |
2012-11-22 |
Mederis Diabetes, Llc |
Improved peptide pharmaceuticals for insulin resistance
|
|
WO2012162547A2
(en)
|
2011-05-25 |
2012-11-29 |
Amylin Pharmaceuticals, Inc. |
Long duration dual hormone conjugates
|
|
UA113626C2
(xx)
|
2011-06-02 |
2017-02-27 |
|
Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
|
|
PE20140765A1
(es)
|
2011-06-10 |
2014-06-14 |
Hanmi Science Co Ltd |
Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
|
|
KR102002783B1
(ko)
|
2011-06-10 |
2019-07-24 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
|
|
KR101874401B1
(ko)
|
2011-06-17 |
2018-07-04 |
할로자임, 아이엔씨 |
히알루로난 분해 효소의 안정한 제형
|
|
UA125895C2
(uk)
|
2011-06-17 |
2022-07-06 |
Ханмі Сайенс Ко., Лтд. |
КОН'ЮГАТ, ЩО МІСТИТЬ ПОХІДНУ ОКСИНТОМОДУЛІНУ ТА Fc-ДІЛЯНКУ ІМУНОГЛОБУЛІНУ, ТА ЙОГО ЗАСТОСУВАННЯ
|
|
BR112013032717A2
(pt)
|
2011-06-22 |
2017-01-24 |
Univ Indiana Res & Tech Corp |
coagonistas do receptor de glucagon/glp-1
|
|
EA031230B1
(ru)
|
2011-06-22 |
2018-12-28 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Агонисты глюкагонового рецептора/glp-1-рецептора
|
|
US20140220134A1
(en)
|
2011-06-24 |
2014-08-07 |
Astrazeneca Pharamceuticals LP |
Method for treating diabetes with extended release formulation of glp-1 receptor agonists
|
|
KR101357117B1
(ko)
|
2011-06-28 |
2014-02-06 |
비앤엘델리팜 주식회사 |
폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
|
|
WO2013004983A1
(en)
|
2011-07-04 |
2013-01-10 |
Imperial Innovations Limited |
Novel compounds and their effects on feeding behaviour
|
|
EP2729481B1
(en)
|
2011-07-08 |
2018-10-17 |
Amylin Pharmaceuticals, LLC |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
|
BR112014002986A2
(pt)
|
2011-08-10 |
2017-06-13 |
Adocia |
composição sob a forma de uma solução injetável, e formulação de dose única
|
|
JP6169079B2
(ja)
|
2011-08-24 |
2017-07-26 |
フェーズバイオ ファーマシューティカルズ，インコーポレイテッド |
徐放のための活性剤の製剤
|
|
WO2013029279A1
(zh)
|
2011-09-03 |
2013-03-07 |
深圳市健元医药科技有限公司 |
新的glp-ⅰ类似物及其制备方法和用途
|
|
CA2849673A1
(en)
|
2011-09-23 |
2013-03-28 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
EP2771024B1
(en)
|
2011-10-28 |
2018-11-28 |
Sanofi-Aventis Deutschland GmbH |
Treatment protocol of diabetes type 2
|
|
CN102363633B
(zh)
|
2011-11-16 |
2013-11-20 |
天津拓飞生物科技有限公司 |
胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
|
|
CN103957927B
(zh)
|
2011-11-17 |
2016-11-09 |
印第安纳大学研究及科技有限公司 |
呈现糖皮质激素受体活性的胰高血糖素超家族肽
|
|
IN2014KN01341A
(cg-RX-API-DMAC7.html)
|
2011-11-29 |
2015-10-16 |
Jurox Pty Ltd |
|
|
SMT202200355T1
(it)
|
2011-12-16 |
2022-11-18 |
Modernatx Inc |
Composizioni di mrna modificato
|
|
SG11201402640SA
(en)
|
2011-12-22 |
2014-10-30 |
Pfizer |
Anti-diabetic compounds
|
|
PE20142113A1
(es)
|
2011-12-23 |
2014-12-03 |
Zealand Pharma As |
Analogos de glucagon
|
|
EP2797585A4
(en)
|
2011-12-29 |
2015-10-07 |
Latitude Pharmaceuticals Inc |
STABILIZED GLUCAGONNANOULULSIONS
|
|
CN107583039A
(zh)
|
2012-01-09 |
2018-01-16 |
阿道恰公司 |
Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
|
|
WO2013148871A1
(en)
|
2012-03-28 |
2013-10-03 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides
|
|
US20150133373A1
(en)
|
2012-03-28 |
2015-05-14 |
Amylin Pharmaceuticals, Llc |
Transmucosal delivery of engineered polypeptides
|
|
EP2834260A4
(en)
|
2012-04-02 |
2016-08-10 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
|
|
CN108949772A
(zh)
|
2012-04-02 |
2018-12-07 |
现代泰克斯公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
CN102649947A
(zh)
|
2012-04-20 |
2012-08-29 |
无锡和邦生物科技有限公司 |
一种用于测定glp-1及其功能类似物生物活性的细胞株及其应用
|
|
EP2841090A1
(en)
|
2012-04-24 |
2015-03-04 |
Amylin Pharmaceuticals, LLC |
Site-specific enzymatic modification of exendins and analogs thereof
|
|
US20130289241A1
(en)
|
2012-04-26 |
2013-10-31 |
Shanghai Ambiopharm, Inc. |
Method for preparing exenatide
|
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
WO2013182217A1
(en)
|
2012-04-27 |
2013-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
WO2013164484A1
(en)
|
2012-05-03 |
2013-11-07 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
|
KR102184241B1
(ko)
|
2012-05-03 |
2020-12-01 |
질랜드 파마 에이/에스 |
Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법
|
|
EP2664374A1
(en)
|
2012-05-15 |
2013-11-20 |
F. Hoffmann-La Roche AG |
Lysin-glutamic acid dipeptide derivatives
|
|
CN103421094A
(zh)
|
2012-05-24 |
2013-12-04 |
上海医药工业研究院 |
一种具有epo类似活性的多肽化合物
|
|
US20150174209A1
(en)
|
2012-05-25 |
2015-06-25 |
Amylin Pharmaceuticals. Llc |
Insulin-pramlintide compositions and methods for making and using them
|
|
IN2014KN02830A
(cg-RX-API-DMAC7.html)
|
2012-06-14 |
2015-05-08 |
Sanofi Sa |
|
|
AU2013277372B2
(en)
|
2012-06-21 |
2018-03-29 |
Indiana University Research And Technology Corporation |
Analogs of glucagon exhibiting GIP receptor activity
|
|
EP2864351B1
(en)
|
2012-06-21 |
2016-08-10 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
|
CA2878457C
(en)
|
2012-07-12 |
2021-01-19 |
Mannkind Corporation |
Dry powder drug delivery systems and methods
|
|
ES2620111T3
(es)
|
2012-07-23 |
2017-06-27 |
Zealand Pharma A/S |
Análogos de glucagón
|
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
|
AR094821A1
(es)
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
WO2014027254A1
(en)
|
2012-08-14 |
2014-02-20 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
WO2014027253A1
(en)
|
2012-08-14 |
2014-02-20 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
CN102816244A
(zh)
|
2012-08-23 |
2012-12-12 |
无锡和邦生物科技有限公司 |
一种Exendin-4肽与人血清白蛋白HSA的融合蛋白及其制备方法
|
|
CN102827270A
(zh)
|
2012-09-13 |
2012-12-19 |
无锡和邦生物科技有限公司 |
一种聚乙二醇化艾塞那肽衍生物及其用途
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
US9546205B2
(en)
|
2012-09-17 |
2017-01-17 |
Imperial Innovations Limited |
Peptide analogues of glucagon and GLP1
|
|
WO2014049610A2
(en)
|
2012-09-26 |
2014-04-03 |
Cadila Healthcare Limited |
Peptides as gip, glp-1 and glucagon receptors triple-agonist
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
WO2014073842A1
(en)
|
2012-11-06 |
2014-05-15 |
Hanmi Pharm. Co., Ltd. |
Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
|
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
KR102365582B1
(ko)
|
2012-11-20 |
2022-02-18 |
메더리스 다이어비티즈, 엘엘씨 |
인슐린 저항성에 대한 개선된 펩티드 약제
|
|
TWI674270B
(zh)
|
2012-12-11 |
2019-10-11 |
英商梅迪繆思有限公司 |
用於治療肥胖之升糖素與glp-1共促效劑
|
|
RS57531B1
(sr)
|
2012-12-21 |
2018-10-31 |
Sanofi Sa |
Derivati eksendina-4 kao dualni glp1/gip- ili trigonalni glp1/gip/glukagon agonisti
|
|
CN103908657A
(zh)
|
2012-12-31 |
2014-07-09 |
复旦大学附属华山医院 |
胰升糖素样肽-1类似物在制备眼科疾病药物中的用途
|
|
EP3238734A1
(en)
|
2013-03-14 |
2017-11-01 |
Medimmune Limited |
Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
|
|
WO2014158900A1
(en)
|
2013-03-14 |
2014-10-02 |
Indiana University Research And Technology Corporation |
Insulin-incretin conjugates
|
|
CN105324125A
(zh)
|
2013-03-15 |
2016-02-10 |
印第安纳大学研究及科技有限公司 |
具有长效的前体药物
|
|
WO2014170496A1
(en)
|
2013-04-18 |
2014-10-23 |
Novo Nordisk A/S |
Stable, protracted glp-1/glucagon receptor co-agonists for medical use
|
|
JP2014227368A
(ja)
|
2013-05-21 |
2014-12-08 |
国立大学法人帯広畜産大学 |
糖尿病および高血糖状態の処置のためのグルカゴンアナログ
|
|
CN103304660B
(zh)
|
2013-07-12 |
2016-08-10 |
上海昂博生物技术有限公司 |
一种利拉鲁肽的合成方法
|
|
CN103405753B
(zh)
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
|
US9896495B2
(en)
|
2013-10-17 |
2018-02-20 |
Zealand Pharma A/S |
Acylated glucagon analogues
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
CA2929107C
(en)
|
2013-11-06 |
2023-09-26 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
|
TW201609798A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
Ｅｘｅｎｄｉｎ－４胜肽類似物
|
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
WO2015086731A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
|
|
EP3080150B1
(en)
|
2013-12-13 |
2018-08-01 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
WO2015086729A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
CN103665148B
(zh)
|
2013-12-17 |
2016-05-11 |
中国药科大学 |
一种可口服给药的降糖多肽及其制法和用途
|
|
CN103980358B
(zh)
|
2014-01-03 |
2016-08-31 |
杭州阿诺生物医药科技股份有限公司 |
一种制备利拉鲁肽的方法
|
|
KR20160104724A
(ko)
|
2014-01-09 |
2016-09-05 |
사노피 |
인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
|
|
CN105899191B
(zh)
|
2014-01-09 |
2020-06-16 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
|
|
GB201404002D0
(en)
|
2014-03-06 |
2014-04-23 |
Imp Innovations Ltd |
Novel compounds
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
CN106519015B
(zh)
|
2014-09-23 |
2020-04-17 |
深圳市图微安创科技开发有限公司 |
胃泌酸调节素类似物
|
|
US9988430B2
(en)
|
2014-10-10 |
2018-06-05 |
Novo Nordisk A/S |
Stable GLP-1 based GLP-1/glucagon receptor co-agonists
|
|
EP3825324A1
(en)
|
2014-10-24 |
2021-05-26 |
Merck Sharp & Dohme Corp. |
Co-agonists of the glucagon and glp-1 receptors
|
|
WO2016198604A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
|
|
WO2016198624A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
|